Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 56 results for hypercholesterolaemia

  1. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Cardiovascular disease prevention: risk assessment (general population) (IND269)

    This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    15 August 2024

  3. Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)

    This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    General practice indicators suitable for use in QOF
    Published
    15 August 2024

  4. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.

    Highly specialised technologies guidance
    Published
    21 October 2020
    View recommendations

    Sections for HST13

  5. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    23 July 2025
    View quality statements

    Sections for QS100

  6. Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]

    Awaiting development Reference number: GID-TA11698 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued Reference number: GID-TA11175

    Technology appraisal guidance
    Discontinued

  8. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  9. What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH who are treated with statin therapy?

    Source guidance details Comes from guidance Familial hypercholesterolaemia: identification and management Number CG71 Date

    Research recommendation
    Published
    15 November 2019

  10. What is the clinical effectiveness and safety of differing doses of lipid-modifying therapy in children with FH?

    Source guidance details Comes from guidance Familial hypercholesterolaemia: identification and management Number CG71 Date

    Research recommendation
    Published
    15 November 2019

  11. What are the implications of FH for the safety of a mother during pregnancy and what are the risks of fetal malformations attributable to pharmacological therapies

    Source guidance details Comes from guidance Familial hypercholesterolaemia: identification and management Number CG71 Date

    Research recommendation
    Published
    15 November 2019

  12. What is the utility of routine cardiovascular evaluation for asymptomatic people with FH?

    Source guidance details Comes from guidance Familial hypercholesterolaemia: identification and management Number CG71 Date

    Research recommendation
    Published
    15 November 2019

  13. What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH?

    Source guidance details Comes from guidance Familial hypercholesterolaemia: identification and management Number CG71 Date

    Research recommendation
    Published
    15 November 2019

  14. What is the clinical and cost effectiveness of using different thresholds of LDL‑C concentration in primary care case finding?

    Source guidance details Comes from guidance Familial hypercholesterolaemia: identification and management Number CG71 Date

    Research recommendation
    Published
    15 November 2019

  15. Lipids disorders: FH assessment (29 years and under) (IND203)

    This indicator covers the percentage of people aged 29 years and under, with a total cholesterol concentration greater than 7.5 mmol/l that are assessed against the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM182

    General practice indicators suitable for use outside of QOF
    Published
    31 July 2019